Drug Profile
AR 25
Alternative Names: AR25Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Arbor Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ear disorders; Respiratory tract disorders
Most Recent Events
- 28 Jun 2022 Discontinued - Preregistration for Ear disorders (In children) in USA (unspecified route) (Azurity Pharmaceuticals pipeline, June 2022)
- 28 Jun 2022 Discontinued - Preregistration for Respiratory tract disorders (In children) in USA (unspecified route) (Azurity Pharmaceuticals pipeline, June 2022)
- 05 Mar 2020 Preregistration for Ear disorders (In children) in USA (unspecified route) before March 2020 (Arbor pharmaceuticals March 2020)